Clinical Trial

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2020 (before its estimated May 23, 2023 completion). Its status may not reflect the trial's current state.
Summary
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-02-21.
Trial Details
NCT Number NCT04283006
Lead Sponsor He Huang
Collaborators: Yake Biotechnology Ltd.
Conditions Relapsed and Refractory, Lymphoid Hematological Malignancies
Enrollment 100 participants
Start Date 2018-05-23
Primary Completion 2023-05-23 (estimated)
Study Completion 2028-05-23 (estimated)
Updated on ClinicalTrials.gov 2020-08-21